216 related articles for article (PubMed ID: 24469344)
21. Vascular responses to drug-eluting and bare metal stents in diabetic/hypercholesterolemic and nonatherosclerotic porcine coronary arteries.
Llano R; Winsor-Hines D; Patel DB; Seifert PS; Hamamdzic D; Wilson GJ; Wang H; Keane MG; Huibregtse BA; Wilensky RL
Circ Cardiovasc Interv; 2011 Oct; 4(5):438-46. PubMed ID: 21972400
[TBL] [Abstract][Full Text] [Related]
22. Endothelial Barrier Protein Expression in Biodegradable Polymer Sirolimus-Eluting Versus Durable Polymer Everolimus-Eluting Metallic Stents.
Mori H; Cheng Q; Lutter C; Smith S; Guo L; Kutyna M; Torii S; Harari E; Acampado E; Joner M; Kolodgie FD; Virmani R; Finn AV
JACC Cardiovasc Interv; 2017 Dec; 10(23):2375-2387. PubMed ID: 29102583
[TBL] [Abstract][Full Text] [Related]
23. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
[TBL] [Abstract][Full Text] [Related]
24. Comparisons of early vascular reactions in biodegradable and durable polymer-based drug-eluting stents in the porcine coronary artery.
Ijichi T; Nakazawa G; Torii S; Nagamatsu H; Yoshikawa A; Souba J; Isobe A; Hagiwara H; Ikari Y
PLoS One; 2019; 14(1):e0209841. PubMed ID: 30629613
[TBL] [Abstract][Full Text] [Related]
25. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A
Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095
[TBL] [Abstract][Full Text] [Related]
26. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis.
Kang SH; Park KW; Kang DY; Lim WH; Park KT; Han JK; Kang HJ; Koo BK; Oh BH; Park YB; Kandzari DE; Cohen DJ; Hwang SS; Kim HS
Eur Heart J; 2014 May; 35(17):1147-58. PubMed ID: 24459196
[TBL] [Abstract][Full Text] [Related]
27. Six-month follow-up evaluation for everolimus-eluting stents by intracoronary optical coherence tomography: comparison with paclitaxel-eluting stents.
Takano M; Murakami D; Yamamoto M; Kurihara O; Murai K; Inami T; Kimata N; Ohba T; Seino Y; Mizuno K
Int J Cardiol; 2013 Jun; 166(1):181-6. PubMed ID: 22075410
[TBL] [Abstract][Full Text] [Related]
28. Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting stents.
van Beusekom HM; Sorop O; van den Heuvel M; Onuma Y; Duncker DJ; Danser AH; van der Giessen WJ
EuroIntervention; 2010 May; 6(1):117-25. PubMed ID: 20542807
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a novel slow-release paclitaxel-eluting stent with a bioabsorbable polymeric surface coating.
Jabara R; Chronos N; Conway D; Molema W; Robinson K
JACC Cardiovasc Interv; 2008 Feb; 1(1):81-7. PubMed ID: 19393150
[TBL] [Abstract][Full Text] [Related]
30. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
[TBL] [Abstract][Full Text] [Related]
31. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis.
Cremers B; Milewski K; Clever YP; Aboodi MS; Biedermann M; Thim T; Kelsch B; Kaluza GL; Scheller B; Granada JF
Catheter Cardiovasc Interv; 2012 Oct; 80(4):603-10. PubMed ID: 22511557
[TBL] [Abstract][Full Text] [Related]
33. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.
Adriaenssens T; Dens J; Ughi G; Bennett J; Dubois C; Sinnaeve P; Wiyono S; Coosemans M; Belmans A; D'hooge J; Vrolix M; Desmet W
EuroIntervention; 2014 Aug; 10(4):439-48. PubMed ID: 25138182
[TBL] [Abstract][Full Text] [Related]
34. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.
Nakazawa G; Finn AV; John MC; Kolodgie FD; Virmani R
Am J Cardiol; 2007 Oct; 100(8B):36M-44M. PubMed ID: 17950831
[TBL] [Abstract][Full Text] [Related]
35. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
36. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
37. Low-dose paclitaxel elution by novel bioerodible sol-gel coating on stents inhibits neointima with low toxicity in porcine coronary arteries.
Shinke T; Geva S; Pendyala L; Jabara R; Li J; Chen JP; Venegoni A; Colley K; Klein R; Chronos N; Robinson K; Hou D
Int J Cardiol; 2009 Jun; 135(1):93-101. PubMed ID: 18692915
[TBL] [Abstract][Full Text] [Related]
38. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
39. Comparison of paclitaxel-eluting vs. everolimus-eluting stents implanted simultaneously in different lesions of the same coronary artery: 12-month follow-up with optical coherence tomography.
de la Torre Hernández JM; Lee DH; Garcia-Camarero T; Sainz Laso F; Zueco J
EuroIntervention; 2013 Dec; 9(8):952-8. PubMed ID: 24384292
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
